drugset / Trial / NCT02137837

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

NCT02137837

RandomizedParallel-groupTriple-blindTreatment

Summary

This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.

Timeline

Start
2014-05
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified Oral
Subject Everolimus Small molecule Oral
Subject Fulvestrant Small molecule Other

Indications